NCI Definition: A rare adenocarcinoma arising from metaplastic bladder epithelium. It is frequently associated with long-standing local irritation. The majority of cases originate from the trigone and the posterior wall of the bladder. 
Bladder adenocarcinomas most frequently harbor alterations in TP53, PIK3CA, SMAD4, RB1, and KRAS .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, PIK3CA Mutation, and SMAD4 Mutation are the most common alterations in bladder adenocarcinoma .
There are 4 clinical trials for bladder adenocarcinoma, of which 4 are open and 0 are completed or closed. Of the trials that contain bladder adenocarcinoma as an inclusion criterion, 1 is phase 1 (1 open) and 3 are phase 2 (3 open).
Nivolumab, cabozantinib, and ipilimumab are the most common interventions in bladder adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.